Fri 15'th Jun 2018
Tekla Life Sciences Investors Stock Analysis
Technical stock analysis for Fri 15'th Jun 2018
Tekla Life Sciences Investors gained 0.16% in the last trading day, rising from $19.03 to $19.06 , and has now gained 3 days in a row. It will be exciting to see whether it manages to continue gaining or take a minor break for the next few days. The price has been going up and down for this period, and there has been a 1.49% gain for the last 2 weeks. Volume fell in the last day by -5 628 shares, and in total, 57 366 shares bought and sold for approximately $0.00. You should take into consideration that a falling volume on higher prices causes divergence and may be an early warning about possible changes for the next couple of days.
|Shorts||0.44% ( 2013-01-15 )|
Tekla Life Sciences Investors has broken the falling short-term trend up. Firstly a slower falling rate is indicated, but this may very well be an early signal of a trend shift. On the reaction there will be support on the roof on the current trend broken, which is $19.05, a level that may pose a second chance to hit a runner. According to fan-theory $20.19 will be the next possible trendtop level and thereby pose a resistance level which may not be broken on the first attempt.
Tekla Life Sciences Investors holds buy signals from both short- and long-term moving averages. In addition, there is a general buy signal from the relation between the two signals where the short-term average is above the long-term average. On corrections down there will be some support from the lines at $18.89 and $18.77. A break down below any of these levels will issue sell signals. A buy signal was issued from a pivot bottom point on Tuesday June 05, 2018, which indicates further gains until a new top pivot has been found. Some negative signals were issued as well, and these may have some influence on the near short-term development. Volume fell during the last trading day while the price increased. This causes a divergence and may be considered as an early warning, but it may also not.
Relative Strength Index (RSI)
RSI14 is 51 and the stock is currently not being overbought or oversold
Support & Resistance
Tekla Life Sciences Investors finds support from accumulated volume at $18.75.
In general the stock tends to have controlled movements, but the low liquidity has increased the risk substantially.
Our recommended stoploss: $18.10 (-5.03%) (This stock has low daily movements and this gives low risk. There is a buy signal from pivot bottom found 8 days ago.)
Very Low Low Medium High Very High
Several short-term signals are positive and the break-up from the falling trend indicates a possible shift for a trend. We believe that the prices around the breaking point will indicate particularly good levels, but we also believe that the current level will hold a possible good buy level for the short-term period.
Trade HQL CFDs with Plus500
Your capital is at risk.
Important: Plus500 doesn't offer signals and it is a CFD service.
Plus500UK Ltd is authorised and regulated by the Financial Conduct Authority (FRN 509909).
Access these features
Auto portfolios gaining up to 30%
Top 5 Candidates in all Lists
Ultimate List Builder